EGETIS THERAPEUTICS

WE CARE

FOR THE RARE

ØU Investor Konference

April 23, 2025

Emcitate® EMA approved and launch in Q2 2025, NDA submission planned for 2025

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Egetis Therapeutics AB (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information"). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not intended for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any other jurisdiction where such distribution would be unlawful. This presentation is not a prospectus or similar document and it has not been approved, registered or reviewed by the Swedish Financial Supervisory Authority nor any governmental authority or stock exchange in any jurisdiction.

The Information has been prepared by the Company and is intended to present background information on the Company, its business and the industry in which it operates. The Information contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any investment activity. The Company shall not have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the Information or otherwise arising in connection with this presentation.

By accessing this Information, you represent that such access does not violate any registration requirements or other legal restrictions in the jurisdiction in which you reside or conduct business. It is especially noted that the Information may not be accessed by persons within the United States or "U.S. Persons" (as defined in Regulation S under the Securities Act of 1933, as amended (the "Securities Act") unless they are qualified institutional buyers "QIBs" as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. Further, the Information may not be accessed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"), a "qualified investors" falling within Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA"), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a "Relevant Person"). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. As a result, you are cautioned not to place undue reliance on such forward-looking statements.

No representation, warranty or undertaking, express or implied, is made by or on behalf of the Company as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaim any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Egetis: building an orphan drug commercial stage company

1. Focus on orphan diseases with proprietary asset **Emcitate®** *(tiratricol)* for the treatment of MCT8 deficiency, a detrimental condition with significant unmet medical need
2. Approved in EU in February 2025
   Confirmation trial under way to complete US NDA dossier - planned submission 2025
3. The first and only approved drug for the treatment of MCT8 deficiency
   A significant market opportunity & potential for expansion into RTH-beta
4. Preparing launch through focused in-house commercial organization in the EU and North America with partnership for RoW
5. A strong team with late-stage orphan clinical development, registration and commercialization experience

A strong regulatory status

ODD — **Orphan drug designation - FDA, EMA**
Market exclusivity 10y (EU) & 7y (US)

Fast track — **Fast track designation - FDA**

PRV — **Rare pediatric disease designation - FDA**
Priority Review Voucher upon approval
Worth approx. $150m

Listed on NASDAQ Stockholm (EGTX)
HQ in Stockholm, Sweden
~40 FTEs

Emcitate® treatment in patients with MCT8 deficiency is associated with survival benefits

In the Triac Trial I, *Emcitate* reached target level serum T3 & improvements in clinically relevant outcome measures



***Emcitate* is associated with a 3x lower risk of mortality in patients with MCT8 deficiency**

Retrospective real-world cohort study in 228 patients - Abstract Aug. 2024

Key demonstrated clinical results

- ✓ Significant and durable reduction of T3 levels within the normal range
- ✓ Normalization of thyrotoxicosis in patients of all ages
- ✓ Improvement of bodyweight and cardiovascular status
- ✓ Beneficial effects are maintained or continue to improve over time, up to six years
- ✓ Benign safety profile

Source: Groeneweg et al; Lancet D&E 2019

Emcitate already supplied globally in managed access programs

Successful traction through Managed access programs confirms the significant commercial potential for Emcitate

Patients Receiving *Emcitate* in Managed Access Programs



- Managed Access Programs allow early access to a medicine prior to regulatory marketing approval, in diseases with high unmet medical needs and no available treatment
- ***Emcitate* is being supplied to around 230 patients in over 25 countries including US, EU**

MCT8 deficiency key features

Estimated incidence: 1 case per 70k male

Median onset of symptoms: 4 months

Median age of diagnosis: 10 months

Patients surviving into adulthood: 70%

Severe intellectual disability: 100%

Ability to sit independently: 8%

Hypotonia, hypertonia & persistence of primitive reflexes: 90%

Severe underweight: 75%

Cardiac arrythmias (PAC): 76%

Median life expectancy: 35 years

Patients dying in childhood: ~30%

Main cause of mortality: Sudden cardiac death

Life long 24-hour care: 100%

Emcitate regulatory pathway in EU & US

Robust data set in an ultra rare genetic disease

Triac Trial I	EMC cohort study	Natural history	Triac Trial II	Survival study	ReTRIACt Trial
N=46	N=67	N=151	N=22	N~228	N=16
• Completed 2018 (Groeneweg, 2019) • Open-label, international, multi-centre study	• Completed 2021 (van Geest, 2022) • N= 27 from Triac Trial I & N= 40 new pts from managed access program	• Retrospective data, 2003 to 2019 (Groeneweg, 2020)	• Open-label, international, multi-centre study • Focus on neurocognition, but did not meet its primary endpoints • 96 weeks safety data in young patients	• Retrospective cohort data • Comparing treated vs untreated patients on survival • Abstract at ETA by EMC	• N= 16 • Placebo controlled • Ongoing

Data included in EMA MAA – EC approval Feb 2025

Data to be included in FDA NDA

Design of the ReTRIACt clinical trial

Requested by the FDA

- A 30-day, randomized placebo-controlled withdrawal study in at least 16 patients
- Design agreed with FDA
- The study allows for inclusion of patients that are already on therapy and patients that are treatment naïve
- Treatment naïve patients require a longer run-in period to stabilize T3 levels around normal range before randomization
- A higher proportion of treatment naïve patients will lead to an extended study duration



Primary endpoint: Proportion of participants who meet the rescue criterion (T3>ULN*) during the 30-day double-blind randomized treatment period

- 19 patients included so far, of which 11 patients have completed the randomized phase and 3 patients are in the run-in period. Several additional patients are currently being evaluated for screening
- 7 sites currently open, including new sites in Georgia, North Carolina, Texas and Florida.
- Recruitment will continue until at least 16 patients have completed the randomized phase

Egetis will update the market as soon as recruitment has been completed, and subsequently when top-line results.
NDA filing planned for 2025

* ULN: Upper Limit of Normal
** Randomized treatment period ends after 30 days or when rescue criterion (T3 >ULN) is met, whichever comes first

A phased EU launch through in-house commercial organization starting in Germany Q2

Wave 1

Initiated right after EU approval

Germany, France, Spain, Italy

Wave 2

Phased on a country-by-country approach

Rest of Europe

2025 | 2026 | **Pricing & Reimbursement processes**

European Thyroid Association (ETA) guidelines published mid 2024, recommending *Emcitate* as long-term therapy for all patients with MCT8 deficiency

Building strong Expert base to advance management of MCT8 deficiency

- Caregivers connected through international & national advocacy groups
- International KOLs & physicians at selected specialist centers
- Global strategy and local interactions with payers

Seizing opportunity for cost-effective value creation

- High disease burden of MCT8 deficiency also confirmed by Egetis sponsored Caregiver and vignette studies
- Targeted stakeholder interactions
- Efficiency gains through global-country team coordination

US commercial preparedness activities under way

Accelerate patient finding efforts by integrating advanced data-driven insights into existing initiatives

Known confirmed diagnosed MCT8 deficiency patients in the US



Naive or treated under early access

Cover major US centers through pre-commercial initiatives

- Hospitals with known MCT8 deficiency patients
- ★ *Emcitate* Expanded Access Program sites



Expanded Access Program, requested by FDA, is a significant asset to both patients and Egetis launch readiness

- Providing early and sustainable access to therapy
- Exposing physicians to *Emcitate* prior to commercial approval
- Collecting real world data to support payer and regulatory communications

Patient-centric implementation

- Partnership with AnovoRx
- Personalized support; drug delivered directly to patient home

Strong financial foundation for strategic execution

Solid cash position

- **Cash position December 31, 2024**: SEK 351 million
- **Number of outstanding shares:** 359,238,126
- **Market Cap:** ~SEK 1.6 billion*
- **Listing venue:** Nasdaq Stockholm, Main Market
- **Ticker:** EGTX

% capital by shareholders



% capital by geographical distribution



Share issuance in Sep. 2024 for SEK 300m (USD 30m)

- Led by Frazier Life Sciences (USD 10 million)
- Supported by international and Swedish healthcare funds
- Subscription at market price

- Clinical development of *Emcitate* for US market authorisation
- Preparatory *Emcitate* launch activities in Europe
- Continued build-up of commercial and medical affairs infrastructure for *Emcitate* commercialization in the EU and US

Note: * March 4, 2025

Upcoming value enhancing key milestones 2025-2026

Emcitate® — **2025-2026**

MCT8 deficiency

- EU launch, in the first country, Germany, during the second quarter of 2025
- Topline results ReTRIACt for US NDA
- Filing US NDA 2025 – fast track designation
- Middle East & North Africa partnership/s
- Japan – Development plan agreed with PMDA
- Potential grant of US Patent - Processes and compounds
- US approval and launch
- US Rare Pediatric Disease Priority Review Voucher

RTH-beta

- Potential initiation of Investigator Initiated Study - Egetis Industry collaborator

Pipeline overview

Emcitate – European Commission approval Feb 13, 2025



EGETIS THERAPEUTICS

Thank you!

Egetis Therapeutics
egetis.com
karl.hard@egetis.com